|1.||Cruikshank, William W: 13 articles (10/2015 - 10/2002)|
|2.||Cruikshank, W W: 11 articles (01/2010 - 04/2000)|
|3.||Lillehoj, Erik P: 5 articles (05/2012 - 12/2004)|
|4.||Center, David M: 5 articles (01/2006 - 10/2002)|
|5.||Skundric, Dusanka S: 4 articles (10/2015 - 11/2005)|
|6.||Cruikshank, William: 4 articles (02/2015 - 01/2006)|
|7.||Reich, Kristian: 4 articles (01/2011 - 04/2002)|
|8.||Kornfeld, Hardy: 4 articles (01/2010 - 03/2003)|
|9.||Schluesener, Hermann J: 4 articles (04/2009 - 01/2004)|
|10.||Lillehoj, Hyun S: 4 articles (12/2006 - 12/2004)|
|1.||Asthma (Bronchial Asthma)
12/01/2002 - "We have extended our previous studies to investigate the role of IL-16 and CD28/B7 costimulation in T-lymphocyte chemotactic activity (TLCA) released from the bronchial mucosa in more severe asthma. "
11/01/2002 - "In the present study, we examined the effect of IL-16 administration in a murine model of allergic asthma. "
08/01/1997 - "This study demonstates that IL-16 is expressed in airway tissues, particularly in the epithelial cells, and that up-regulation of its expression is a feature of allergic asthma. "
06/20/2006 - "Interleukin-16 in asthma."
01/01/2006 - "Further investigation is needed to delineate the mechanisms underlying these findings and the relationship of the IL16 -295 genotype to asthma in other populations."
04/01/1999 - "Supplemental therapy with IL-16 may be a novel and effective treatment for rheumatoid arthritis."
02/01/2016 - "Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis."
01/01/2015 - "Interleukin-16 (IL-16) polymorphisms have been associated with various disease states, and its activity is dysregulated in synovial fibroblasts of individuals with rheumatoid arthritis. "
01/01/2005 - "[Interleukin-16 in pathogenesis in rheumatoid arthritis]."
01/01/2004 - "To investigate the role of interleukin 16 (IL-16) in the development of rheumatoid arthritis (RA) and joint destruction. "
11/01/2013 - "IL-1, IL-6, IL-16, MIP-1α, MCP-1, and TNF-α play a role in the development and progression of silicosis inflammation. "
05/01/2015 - "As silicosis biomarkers, TNF-alpha, TGF-beta, IL-16, PDGF, MMP-2, MMP-9 and MCP-1 have certain significance, further suggesting that early detection rate of patients with silicosis can be improved by employing the multiple indexes discriminate equation."
03/01/2014 - "Seven eligible studies pooling 1678 cases and 1937 controls were quantitatively analyzed to evaluate three IL-16 polymorphisms (rs4778889, rs4072111, rs11556218) and cancer risk. "
03/01/2014 - "To resolve inconsistencies in published data, we performed a meta-analysis of studies of IL-16 polymorphisms and cancer risk. "
03/01/2014 - "This study showed that tissue expression and serum levels of IL-16 increase in association with malignant ovarian tumor development and progression."
03/01/2014 - "In an exploratory study, changes in IL-16 expression in association with OVCA development and progression were determined using ovarian tissues and serum samples from healthy subjects (n = 10) and patients with benign (n = 10) and malignant ovarian tumors at early (n = 8) and late (n = 20) stages. "
01/01/2014 - "With all studies involved, results showed no statistically significant association between IL-16 rs4778889 T/C polymorphism and cancer risk (CC vs. CT+TT: OR=0.74, 95%CI: 0.55-1.02, Ph=0.15; CC+CT vs. TT: OR=0.89, 95%CI: 0.72-1.10, Ph =0.03; CC vs. TT: OR=0.73, 95%CI: 0.53- 1.00, Ph =0.08; CT vs. TT: OR=0.91, 95%CI: 0.79-1.05, Ph =0.08; C vs. T: OR=0.89, 95%CI: 0.74-1.07, Ph =0.02). "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Biological Markers (Surrogate Marker)
|4.||Transforming Growth Factor beta (TGF-beta)
|7.||Interleukin-18 (Interleukin 18)
|9.||Interleukin-6 (Interleukin 6)
|10.||Interleukin-16 (Interleukin 16)
|1.||Drug Therapy (Chemotherapy)
|5.||Highly Active Antiretroviral Therapy (HAART)